|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
12/8/2009 11:27:27 AM
SAN DIEGO, CA. — San Diego-based Crinetics Pharmaceuticals announced today that
it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from
the National Institutes of Health (NIH) to develop G protein-coupled receptor (GPCR)
biosensors for drug discovery applications. The grant supports the Company’s effort to
expand this cutting-edge research tool to drug targets addressing important unmet
medical needs and adapt the technology to formats suitable for routine use in GPCR
drug discovery. GPCR biosensors are one component of the company’s emerging
GPCR Dynamics assay platform.
The biological properties of drugs acting at GPCRs are determined by fundamental
pharmacologic parameters such as ligand binding kinetics, intrinsic efficacy,
desensitization, trafficking, and relative activation of various intracellular signaling
pathways. However, these properties are not typically available with traditional static
assays used to guide medicinal chemistry efforts. Instead, medicinal chemists are
routinely forced to rely on binding assays and cellular functional assays that provide
aggregated and potentially misleading information. Crinetics is developing its GPCR
Dynamics assay platform to support both internal drug discovery programs and
programs originating from corporate partners.
“GPCR biosensors let researchers see properties of drug candidates that are invisible to
currently used static assays. This enables drug discovery teams to make better
decisions, move faster, and reduce clinical failures,” said R. Scott Struthers Ph.D.,
Founder and Chief Scientific Officer of Crinetics Pharmaceuticals. “The NIH SBIR
program has been an important catalyst for the San Diego biotechnology community
and we greatly appreciate their support at this early stage in our Company’s
development.” said Dr. Struthers.
Crinetics Pharmaceuticals Inc. (www.crinetics.com) is a startup company located in the
heart of the San Diego biotechnology community. The company is focused on
developing and applying next generation pharmacology tools within an aggressive drughunter
based culture. The company’s GPCR Dynamics Platform enables lead
optimization based on fundamental pharmacologic properties typically only available for
advanced clinical compounds. Our internal drug discovery pipeline is focused on
endocrine GPCRs that provide biochemical proof-of-concept in early clinical studies and
offer significant therapeutic advances for large markets.
|
|
|
|
|
|
|
|
|
|
|